Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 29, 2026, 3:35 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 553–576 of 621 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Subutex Clear all
Recruiting Phase 2 Interventional

Rapid Outpatient Low-dose Initiation of Buprenorphine for OUD With Fentanyl Use

NCT06379984
View directory record Official record
Conditions
Opioid Use Disorder
Interventions
Buprenorphine
Drug
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 10, 2026 · Synced Oct 29, 2026, 3:35 PM EDT
Recruiting Phase 4 Interventional

A Bundled Intervention to End Opioid Overdoses

NCT07485335
View directory record Official record
Conditions
Opioid Use Disorder, Opioid Overdose
Interventions
Bundled intervention (Experimental), control group, Buprenorphine (Experimental), Scheduled Peer Support Specialist (Experimental), Telemedicine Buprenorphine Treatment
Other · Drug · Behavioral
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
19 Years and older
Enrollment
160 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Oct 2, 2026 · Synced Oct 29, 2026, 3:35 PM EDT
Not listed Not applicable Interventional

Are Adductor Canal Blocks With Bupivacaine and Added Magnesium Better at Managing Post-operative Pain Than Bupivacaine and Added Buprenorphine in Patients Undergoing Same-day Discharge Total Knee Arthroplasty?

NCT05091138
View directory record Official record
Conditions
Post-operative Pain, Acute, Opioid Use
Interventions
Adding Magnesium as an adjuvant to Bupivacaine in the adductor canal block (ACB) for same-day discharge total knee arthroplasty, Adding Buprenorphine as an adjuvant to Bupivacaine in the adductor canal block (ACB) for same-day discharge total knee arthroplasty
Drug
Lead sponsor
Wayne State University
Other
Eligibility
18 Years to 100 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
Pontiac, Michigan
Source: ClinicalTrials.gov public record
Updated Oct 25, 2021 · Synced Oct 29, 2026, 3:35 PM EDT
Completed Not applicable Interventional

Providing PrEP, Hepatitis C Treatment, and MOUD Through Telemedicine at Greensboro SSP

NCT05108935
View directory record Official record
Conditions
Opioid Use, Opioid Use Disorder, Risk Reduction, Hiv, Hepatitis C
Interventions
Suboxone, Truvada, Mavyret
Drug
Lead sponsor
Duke University
Other
Eligibility
18 Years and older
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
2
States / cities
Durham, North Carolina • Greensboro, North Carolina
Source: ClinicalTrials.gov public record
Updated Apr 27, 2023 · Synced Oct 29, 2026, 3:35 PM EDT
Completed Not applicable Interventional

Behavioral Activation for Opioid Use Disorder

NCT05262725
View directory record Official record
Conditions
Opioid Use Disorder
Interventions
Values-based Behavioral Activation
Behavioral
Lead sponsor
University of Minnesota
Other
Eligibility
18 Years and older
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Mar 17, 2023 · Synced Oct 29, 2026, 3:35 PM EDT
Enrolling by invitation Phase 4 Interventional

Houston Emergency Opioid Engagement System

NCT03396276
View directory record Official record
Conditions
Opioid Use Disorder
Interventions
Suboxone, Brief counseling in the ED, Referral to outpatient treatment, Follow-up coaching
Drug · Behavioral
Lead sponsor
The University of Texas Health Science Center, Houston
Other
Eligibility
18 Years and older
Enrollment
3,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2030
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Oct 1, 2025 · Synced Oct 29, 2026, 3:35 PM EDT
Withdrawn Phase 4 Interventional

Psychopharmacological Treatment of Emotional Distress

NCT06133114
View directory record Official record
Conditions
Suicide Crisis Syndrome, Psychological Distress
Interventions
Clonazepam, Olanzapine, Buprenorphine
Drug
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 28, 2026 · Synced Oct 29, 2026, 3:35 PM EDT
Completed Phase 2 Interventional Results available

Safety and Tolerability of Buprenorphine/Naloxone Film Strips

NCT00640835
View directory record Official record
Conditions
Opioid-Related Disorders
Interventions
Buprenorphine/naloxone Film Strip
Drug
Lead sponsor
Indivior Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
382 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008
U.S. locations
3
States / cities
Birmingham, Alabama • Haleyville, Alabama • Jacksonville Beach, Florida
Source: ClinicalTrials.gov public record
Updated Nov 12, 2012 · Synced Oct 29, 2026, 3:35 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Increasing MAT Engagement With Financial Incentives

NCT04585399
View directory record Official record
Conditions
Opioid-use Disorder
Interventions
Contingency management
Behavioral
Lead sponsor
Rowan University
Other
Eligibility
18 Years and older
Enrollment
92 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2024
U.S. locations
1
States / cities
Camden, New Jersey
Source: ClinicalTrials.gov public record
Updated Apr 4, 2025 · Synced Oct 29, 2026, 3:35 PM EDT
Recruiting Not applicable Interventional

Coordinating Outpatient bupreNorphiNe for Emergency Care and Continuing Treatment

NCT07024498
View directory record Official record
Conditions
Opioid Use Disorder
Interventions
care coordination implementation strategies
Other
Lead sponsor
University of California, Davis
Other
Eligibility
14 Years and older
Enrollment
3,492 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
4
States / cities
El Centro, California • Irvine, California • Placerville, California + 1 more
Source: ClinicalTrials.gov public record
Updated Jun 12, 2026 · Synced Oct 29, 2026, 3:35 PM EDT
Completed Phase 2 Interventional

Buprenorphine Dosing Interval - 5

NCT00000209
View directory record Official record
Conditions
Opioid-Related Disorders
Interventions
Buprenorphine
Drug
Lead sponsor
National Institute on Drug Abuse (NIDA)
NIH
Eligibility
21 Years to 50 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1992
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Aug 17, 2005 · Synced Oct 29, 2026, 3:35 PM EDT
Completed Phase 3 Interventional Results available

Evaluating Naltrexone for Use in Conjunction With Buprenorphine in Adults With Opioid Use Disorder Transitioning From Buprenorphine Maintenance Prior to First Dose of VIVITROL

NCT02696434
View directory record Official record
Conditions
Opioid Use Disorder
Interventions
Naltrexone, Placebo, Buprenorphine
Drug
Lead sponsor
Alkermes, Inc.
Industry
Eligibility
18 Years to 60 Years
Enrollment
101 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2017
U.S. locations
9
States / cities
Lauderhill, Florida • Oakland Park, Florida • Winfield, Illinois + 6 more
Source: ClinicalTrials.gov public record
Updated Feb 12, 2019 · Synced Oct 29, 2026, 3:35 PM EDT
Completed No phase listed Observational

Fetal Neurobehavior in Poly-drug Dependent Women

NCT00653692
View directory record Official record
Conditions
Poly Drug Exposed Pregnancies
Interventions
Not listed
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years to 41 Years · Female only
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Feb 21, 2013 · Synced Oct 29, 2026, 3:35 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Buprenorphine Disposition and CYP3A

NCT01576575
View directory record Official record
Conditions
Healthy
Interventions
Buprenorphine Control, Buprenorphine + Rifampin, Buprenorphine + Grapefruit juice, Buprenorphine + Ketoconazole
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years to 50 Years
Enrollment
21 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2014
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Jan 22, 2020 · Synced Oct 29, 2026, 3:35 PM EDT
Terminated Phase 1 Interventional

Acute Pain Management in Patients on Opioid Replacement Therapy

NCT03933865
View directory record Official record
Conditions
Opioid-use Disorder, Pain, Acute
Interventions
HYDROmorphone Injectable Solution, Ketamine, Placebos
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years to 60 Years
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Oct 10, 2022 · Synced Oct 29, 2026, 3:35 PM EDT
Withdrawn Phase 3 Interventional Accepts healthy volunteers

Comparison of Three Opioid Detoxification Treatment Regimens

NCT03678792
View directory record Official record
Conditions
Opioid-Related Disorders, Opioid Withdrawal
Interventions
Buprenorphine/naloxone, Morphine, Tramadol
Drug
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
18 Years to 65 Years
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2020
U.S. locations
1
States / cities
Richmond, Virginia
Source: ClinicalTrials.gov public record
Updated Nov 5, 2019 · Synced Oct 29, 2026, 3:35 PM EDT
Completed Phase 2 Interventional

Buprenorphine Maintenance for Opiate Dependence - 6

NCT00000357
View directory record Official record
Conditions
Opioid-Related Disorders, Substance-Related Disorders
Interventions
Buprenorphine
Drug
Lead sponsor
National Institute on Drug Abuse (NIDA)
NIH
Eligibility
Male only
Healthy volunteers
Healthy volunteers not accepted
Timeline
1992 – 1993
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jan 12, 2017 · Synced Oct 29, 2026, 3:35 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Bioequivalency Study of Buprenorphine Hydrochloride 8 mg Tablet Under Fasted Conditions

NCT00992095
View directory record Official record
Conditions
Opioid-Related Disorders
Interventions
buprenorphine hydrochloride
Drug
Lead sponsor
Roxane Laboratories
Industry
Eligibility
18 Years to 45 Years
Enrollment
48 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Jan 23, 2018 · Synced Oct 29, 2026, 3:35 PM EDT
Completed Phase 2 Interventional

HIV Risk Reduction and Drug Abuse Treatment in Malaysia

NCT00383045
View directory record Official record
Conditions
Opiate Dependence
Interventions
Buprenorphine/Subutex, Naltrexone, Drug counseling
Drug · Procedure
Lead sponsor
Yale University
Other
Eligibility
18 Years to 65 Years · Male only
Enrollment
180 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2007
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Mar 31, 2020 · Synced Oct 29, 2026, 3:35 PM EDT
Completed Phase 2 Interventional

Suvorexant as an Adjunct to Buprenorphine in Persons Who Use Fentanyl

NCT05145764
View directory record Official record
Conditions
Suvorexant, Placebo, Opioid Use Disorder
Interventions
Suvorexant, Placebo
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years to 65 Years
Enrollment
76 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 10, 2026 · Synced Oct 29, 2026, 3:35 PM EDT
Completed Not applicable Interventional Results available

Treatment of Pregnant Women With OUD

NCT04240392
View directory record Official record
Conditions
Opioid-use Disorder
Interventions
Collaborative Care (CC), Extension for Community Healthcare Outcomes (ECHO)
Behavioral
Lead sponsor
Yale University
Other
Eligibility
18 Years and older · Female only
Enrollment
230 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2024
U.S. locations
11
States / cities
Hartford, Connecticut • New Britain, Connecticut • New Haven, Connecticut + 7 more
Source: ClinicalTrials.gov public record
Updated May 21, 2025 · Synced Oct 29, 2026, 3:35 PM EDT
Completed Phase 3 Interventional Results available

Medication Treatment for Opioid Use Disorder in Expectant Mothers

NCT03918850
View directory record Official record
Conditions
Opioid-Related Disorders, Drug Addiction, Pregnancy Related, Substance Abuse, Drug Abuse, Neonatal Abstinence Syndrome, Neonatal Opioid Withdrawal Syndrome, Drug Abuse in Pregnancy
Interventions
Buprenorphine Injection, Buprenorphine Sublingual Product
Drug
Lead sponsor
T. John Winhusen, PhD
Other
Eligibility
18 Years to 41 Years · Female only
Enrollment
140 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
12
States / cities
Jacksonville, Florida • Boston, Massachusetts • Albuquerque, New Mexico + 8 more
Source: ClinicalTrials.gov public record
Updated Jun 4, 2026 · Synced Oct 29, 2026, 3:35 PM EDT
Completed Phase 2 Interventional

A Laboratory Model for Heroin Abuse Medications - 8

NCT00000273
View directory record Official record
Conditions
Heroin Dependence, Opioid-Related Disorders, Substance-Related Disorders
Interventions
opiates
Drug
Lead sponsor
New York State Psychiatric Institute
Other
Eligibility
18 Years to 45 Years
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1995 – 2005
U.S. locations
2
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 5, 2017 · Synced Oct 29, 2026, 3:35 PM EDT
Completed Early Phase 1 Interventional Results available

Galantamine and CBT4CBT Pilot to Prevent Relapse.

NCT03547622
View directory record Official record
Conditions
Methadone or Buprenorphine Detoxoxification
Interventions
MAT taper with galantamine, MAT taper with placebo
Drug
Lead sponsor
Yale University
Other
Eligibility
18 Years to 65 Years
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Aug 19, 2022 · Synced Oct 29, 2026, 3:35 PM EDT